Kiniksa Pharmaceuticals, Ltd. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +56.7%
EBITDA: +1219.7%
EBIT: +689.9%
EPS: +517.0%
Free cash flow: +275.5%
Operating cash flow: +276.7%

Forward estimates

Revenue: +22.9%
EBITDA: —
EPS: +39.1%

Three-year CAGR

Revenue: +45.5%
EBITDA: +88.8%
EBIT: +99.2%
Net income: -31.5%
EPS: -32.8%
Free cash flow: +64.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.